T
Tislelizumab
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
Yes
Post-marketing information
Patient Alert Card
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Medical Assistance Fund
Active ingredient: Tislelizumab
General information
Subsidy Information and Financing Scheme
[MAF] Tislelizumab (Tevimbra) Concentrate For Solution For Infusion 100 mg/10 mL
Tislelizumab in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have PD-L1 expression on ≥50% of tumour cells, with no EGFR or ALK genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Tislelizumab in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). Patients with locally advanced squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic NSCLC.
Tislelizumab in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma.
Treatment of patients with unresectable, recurrent, locally advanced, or metastatic oesophageal squamous cell carcinoma after prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable, recurrent, locally advanced, or metastatic setting.
Tislelizumab in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
[MSHL] Tislelizumab Concentrate For Solution For Infusion 100 mg/10 mL
Tislelizumab in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have PD-L1 expression on ≥50% of tumour cells, with no EGFR or ALK genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Tislelizumab in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC). Patients with locally advanced squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Treatment of patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for locally advanced or metastatic NSCLC.
Treatment of patients with unresectable, recurrent, locally advanced, or metastatic oesophageal squamous cell carcinoma after prior chemotherapy. Patients must not have received prior treatment with a PD-1/PD-L1 inhibitor for this condition in the unresectable, recurrent, locally advanced, or metastatic setting.
Tislelizumab in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma.
Tislelizumab in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
Drug Guidance for Subsidy
The Ministry of Health’s Drug Advisory Committee has recommended:
Tislelizumab 100 mg/10 mL concentrate for solution for infusion, in combination with platinum-doublet chemotherapy, for untreated locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC), in patients whose tumours have programmed death-ligand 1 (PD-L1) expression on ≥50% of tumour cells, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase genomic tumour aberrations. Patients with locally advanced non-squamous NSCLC must not be candidates for surgical resection or platinum-based chemoradiation.
Funding status
[R] Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 September 2025.
Clinical indication, subsidy class and MediShield Life claim limit for tislelizumab are provided in the Annex.
The Ministry of Health’s Drug Advisory Committee has recommended:
Tislelizumab 100 mg/10 mL concentrate for solution for infusion for the following indications:
in combination with platinum-doublet chemotherapy for untreated locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC);
treatment of patients with locally advanced or metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy;
in combination with platinum-based chemotherapy for untreated, unresectable, locally advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC);
treatment of patients with unresectable, recurrent, locally advanced, or metastatic OSCC after prior chemotherapy; and
in combination with chemotherapy for first-line systemic treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.
in view of acceptable clinical effectiveness and safety, an acceptable pricing proposal by the company, and potential cost savings to the healthcare system.
Funding status
[R] Tislelizumab 100 mg/10 mL concentrate for solution for infusion is recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications from 1 September 2025.
Clinical indications, subsidy class and MediShield Life claim limits for tislelizumab are provided in the Annex.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tevimbra Concentrate For Solution For Infusion 100 mg/10 mL |
|